Akhtar Noreen, Jabeen Ishrat
Research Centre for Modeling and Simulation (RCMS), National University of Sciences and Technology (NUST), Islamabad, Pakistan.
PLoS One. 2016 Dec 30;11(12):e0168806. doi: 10.1371/journal.pone.0168806. eCollection 2016.
Protein kinase B-β (PKBβ/Akt2) is a serine/threonine-specific protein kinase that has emerged as one of the most important regulators of cell growth, differentiation, and division. Upregulation of Akt2 in various human carcinomas, including ovarian, breast, and pancreatic, is a well-known tumorigenesis phenomenon. Early on, the concept of the simultaneous administration of anticancer drugs with inhibitors of Akt2 was advocated to overcome cell proliferation in the chemotherapeutic treatment of cancer. However, clinical studies have not lived up to the high expectations, and several phase II and phase III clinical studies have been terminated prematurely because of severe side effects related to the non-selective isomeric inhibition of Akt2. The notion that the sequence identity of pleckstrin homology (PH) domains within Akt-isoforms is less than 30% might indicate the possibility of the development of selective antagonists against the Akt2 PH domain. Therefore, in this study, various in silico tools were utilized to explore the hypothesis that quinoline-type inhibitors bind in the Akt2 PH domain. A Grid-Independent Molecular Descriptor (GRIND) analysis indicated that two hydrogen bond acceptors, two hydrogen bond donors and one hydrophobic feature at a certain distance from each other were important for the selective inhibition of Akt2. Our docking results delineated the importance of Lys30 as an anchor point for mapping the distances of important amino acid residues in the binding pocket, including Lys14, Glu17, Arg25, Asn53, Asn54 and Arg86. The binding regions identified complement the GRIND-based pharmacophoric features.
蛋白激酶B-β(PKBβ/Akt2)是一种丝氨酸/苏氨酸特异性蛋白激酶,已成为细胞生长、分化和分裂的最重要调节因子之一。Akt2在包括卵巢癌、乳腺癌和胰腺癌在内的各种人类癌症中的上调是一种众所周知的肿瘤发生现象。早期,有人主张将抗癌药物与Akt2抑制剂同时给药,以克服癌症化疗中的细胞增殖。然而,临床研究并未达到人们的高度期望,几项II期和III期临床研究因与Akt2的非选择性异构体抑制相关的严重副作用而提前终止。Akt异构体中pleckstrin同源(PH)结构域的序列同一性小于30%这一观点可能表明开发针对Akt2 PH结构域的选择性拮抗剂的可能性。因此,在本研究中,利用各种计算机工具来探索喹啉类抑制剂结合在Akt2 PH结构域中的假设。网格独立分子描述符(GRIND)分析表明,两个氢键受体、两个氢键供体和一个彼此相距一定距离的疏水特征对于Akt2的选择性抑制很重要。我们的对接结果描绘了Lys30作为一个锚点的重要性,用于确定结合口袋中重要氨基酸残基(包括Lys14、Glu17、Arg25、Asn53、Asn54和Arg86)的距离。所确定的结合区域与基于GRIND的药效团特征互补。